Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$12.75 USD
+1.04 (8.88%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $12.60 -0.15 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 121 - 127 ( 127 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Stage Set for PTI-125 to Unfold in 2020; Reit Buy and Raise PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Expecting PTI-125?s Momentum to Keep Going in 2020; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Further Advancement of PTI-125 in Alzheimer?s Disease Continues to Be Intriguing
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Data at CTAD Supports PTI-125''s Potential to Slow Down Alzheimer''s Progression
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Positive Phase 2a Clinical Results With PTI-125 in Alzheimer?s Patients: Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
2Q19 Recap and What to Look for in 2H19: Reiterate Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Acquiring a Taste for Cassava; Initiating With a Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V